SCHEMBL26617205

SCHEMBL26617205

Cc1ccc(-c2cccc(C(=O)NCc3cccc[n+]3[O-])c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.48
▸ NR1H4 Q96RI1 1/20 0.48
▸ UTS2R Q9UKP6 4/20 0.45
▸ CFD P00746 1/20 0.44
▸ AKR1C4 P17516 2/20 0.44
▸ AKR1C3 P42330 2/20 0.44
▸ AKR1C2 P52895 1/20 0.44
▸ ADAMTS7 Q9UKP4 1/20 0.44
▸ DRD4 P21917 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ SENP1 Q9P0U3 1/20 0.43
▸ ERN1 O75460 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26617185 0.92 DRD4 (0.49) EPHX2NR1H4CFDDRD4HPGD
SCHEMBL26617213 0.92 EPHX2 (0.56) EPHX2NR1H4CFDKDM4EALDH1A1
SCHEMBL26617216 0.89 EPHX2 (0.49) EPHX2NR1H4UTS2RCFDALDH1A1
SCHEMBL26704136 0.89 MEN1 (0.50) EPHX2NR1H4CFDSENP1ERN1
SCHEMBL26617227 0.88 AURKA (0.49) EPHX2NR1H4CFDSENP1ERN1
SCHEMBL26617231 0.88 EPHX2 (0.46) EPHX2NR1H4UTS2RCFDSMN1; SMN2
SCHEMBL26617175 0.88 DRD4 (0.48) EPHX2NR1H4CFDDRD4KDM4E
SCHEMBL26617230 0.88 NR1H4 (0.46) EPHX2NR1H4CFDMAPK1KDM4E
SCHEMBL31714575 0.87 EPHX2 (0.45) EPHX2NR1H4CFDDRD4MAPK1
SCHEMBL26617233 0.87 EPHX2 (0.45) EPHX2NR1H4CFDDRD4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 — — US claimed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 — — EP claimed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO claimed
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 — — US disclosed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 — — EP disclosed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO disclosed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SCNN1B, SCN1B, SCN2B EPHX2 1625/4885NR1H4 1118/4885UTS2R 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback